Asparaginase Escherichia coli

DB00023ApprovedInvestigationalProtein Based TherapiesAsparagine-specific Enzyme

Asparaginase Escherichia coli is an asparaginase enzyme from E. coli used as part of treatment regimens for acute lymphoblastic leukemias. Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia.

Protein structure of Asparaginase Escherichia coli
Mechanism
Curator reviewed · 4 references
Primary indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).Curator reviewed · 1 structured indication
Formula / weight
C1377H2208N382O442S17
First approval
Canada, 2016 · United States, 1978 · European Union, 2016
Also known as
Asparaginase · Asparaginase (E. coli) · Asparaginase II · Asparaginase-E.Coli · Colaspase
Code names
Lcf-ASP · MK-965 · NSC-109229 · Re-82-TAD-15
Brand names
  • Rylaze
  • Spectrila

Resolves to

What you can answer from here — as of September 24, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
605Drug interactionsStructured to mechanism, not free text
Sign in
140Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
15Marketed productsAcross 10 countries and 11 labellers
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Asparaginase Escherichia coli, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account